Sugi Predict

Sugi Predict / Compounds / SCHEMBL3146017

SCHEMBL3146017

SCHEMBL3146017

NCc1ccc(-c2cccc(S(=O)(=O)n3ccc(C=CC(=O)NO)c3)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 17/20 0.58
▸ HDAC6 Q9UBN7 16/20 0.58
▸ HDAC8 Q9BY41 16/20 0.57
▸ HDAC3 O15379 16/20 0.57
▸ HDAC2 Q92769 18/20 0.47
▸ HDAC9 Q9UKV0 15/20 0.47
▸ HDAC10 Q969S8 14/20 0.47
▸ HDAC11 Q96DB2 14/20 0.47
▸ HDAC4 P56524 14/20 0.47
▸ HDAC7 Q8WUI4 14/20 0.47
▸ HDAC5 Q9UQL6 14/20 0.47
▸ KDM1A O60341 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ ERBB2 P04626 1/20 0.46
▸ INSR P06213 1/20 0.46
▸ PDGFRB P09619 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3146007 1.00 HDAC1 (0.58) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL296547 0.89 HDAC1 (0.55) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL296548 0.89 HDAC1 (0.55) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3145669 0.88 HDAC6 (0.76) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3145656 0.88 HDAC6 (0.76) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL296534 0.87 HDAC1 (0.73) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL296533 0.87 HDAC1 (0.73) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3145473 0.87 HDAC1 (0.51) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3145488 0.87 HDAC1 (0.51) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3136102 0.86 HDAC1 (0.54) HDAC1HDAC6HDAC8HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS MAIER THOMAS 2010-03-25 — — US claimed
US-7666868-B2 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders 4SC AG (DE) 2010-02-23 — — US claimed
EP-1861365-B1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-07-01 — — EP claimed
US-20080176848-A1 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders NYCOMED GMBH (DE) 2008-07-24 — — US claimed
US-12285410-B2 Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy 4SC AG (DE) 2025-04-29 — — US disclosed
US-20230201161-A1 Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment 4SC AG (DE) 2023-06-29 — — US disclosed
US-20210145799-A1 PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER 4SC AG (DE) 2021-05-20 — — US disclosed
US-20210113528-A1 Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy 4SC AG (DE) 2021-04-22 — — US disclosed
US-20200261418-A1 HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY 4SC AG (DE) 2020-08-20 — — US disclosed
US-8815855-B2 N-sulphonylpyrroles and their use as histone deacetylase inhibitors 4SC AG (DE) 2014-08-26 — — US disclosed
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS MAIER THOMAS 2010-03-25 — — US disclosed
EP-1861365-B1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-07-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145799-A1 PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER HDAC8, TLR8, TLR7 HDAC1 14/4885HDAC6 15/4885HDAC8 1/4885
US-20080176848-A1 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders HDAC1, H1-3, HDAC2 HDAC1 1/4885HDAC6 17/4885HDAC8 16/4885
US-20210113528-A1 Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy HDAC7, HDAC1, HDAC11 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885
US-12285410-B2 Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy HDAC7, HDAC1, HDAC11 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC6 9/4885HDAC8 10/4885
US-20200261418-A1 HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY HDAC4, HDAC5, HDAC9 HDAC1 4/4885HDAC6 10/4885HDAC8 7/4885
US-20230201161-A1 Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC6 16/4885HDAC8 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.